B. P. O'sullivan and S. D. Freedman, Cystic fibrosis. The Lancet, vol.373, pp.1891-1904, 2009.

P. Burgel, Évolutions épidémiologiques de la mucoviscidose en France: perspectives à 10 ans, Archives de Pédiatrie, vol.23, issue.12, pp.30056-30064, 2016.

R. J. Riordan, B. Kerem, N. Alon, R. Rozmahel, Z. Grzelczak et al., Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA, Science, vol.245, issue.4922, pp.1066-1073, 1989.

J. Rommens, M. Iannuzzi, B. Kerem, M. Drumm, G. Melmer et al., Identification of the cystic fibrosis gene: chromosome walking and jumping, Science, vol.245, issue.4922, pp.1059-1065, 1989.

B. Kerem, J. Rommens, J. Buchanan, D. Markiewicz, T. Cox et al., Identification of the cystic fibrosis gene: genetic analysis, Science, vol.245, issue.4922, pp.1073-1080, 1989.

, Cystic Fibrosis Mutation Database, 2020.

, Elborn JS. Cystic fibrosis. The Lancet, vol.388, pp.2519-2531, 2016.

I. Klein, B. Sarkadi, and A. Váradi, An inventory of the human ABC proteins, Biochimica et Biophysica Acta (BBA) -Biomembranes, vol.1461, issue.2, pp.237-262, 1999.

C. Bergeron and A. M. Cantin, Cystic Fibrosis: Pathophysiology of Lung Disease. Seminars in Respiratory and Critical Care Medicine, vol.40, pp.715-726, 2019.

F. Ratjen and G. Döring, Cystic fibrosis. The Lancet, vol.361, pp.681-689, 2003.
URL : https://hal.archives-ouvertes.fr/hal-00614855

R. Montagnac, F. Sanlaville, B. Soto, V. Vuiblet, F. Schillinger et al., Néphrologie & Thérapeutique, vol.5, issue.6, pp.550-558, 2009.

G. Snell, A. Reed, M. Stern, and D. Hadjiliadis, The evolution of lung transplantation for cystic fibrosis: A 2017 update, Journal of Cystic Fibrosis, vol.16, issue.5, pp.553-564, 2017.

A. De and L. Biomédecine, , 2020.

. Ct-12472_kalydeco_ins_avis-2_ct12474 and . Pdf, , 2020.

. Symkevi-/-kalydeco, Haute Autorité de Santé, 2020.

, Trikafta -FDA prescribing information, side effects and uses, Drugs.com, 2020.

S. M. Hoy, Elexacaftor/Ivacaftor/Tezacaftor: First Approval, Drugs, vol.79, issue.18, pp.2001-2007, 2019.

M. Gentzsch and M. A. Mall, Ion Channel Modulators in Cystic Fibrosis, Chest, vol.154, issue.2, pp.383-393, 2018.

M. Skilton, A. Krishan, S. Patel, I. P. Sinha, and K. W. Southern, Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis Cochrane Cystic Fibrosis and Genetic Disorders Group, editor. Cochrane Database of Systematic Reviews, 2019.


K. W. Southern, S. Patel, I. P. Sinha, and S. J. Nevitt, Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis, Cochrane Database of Systematic Reviews, issue.8, p.2020, 2018.


A. L. Stephenson, S. Stanojevic, J. Sykes, and P. Burgel, The changing epidemiology and demography of cystic fibrosis, La Presse Médicale, vol.46, issue.6, pp.87-95, 2017.

S. H. Donaldson and R. C. Boucher, Physiopathologie de la mucoviscidose, Annales Nestlé (Ed. française), vol.64, issue.3, pp.101-109, 2006.

C. Martin, C. Hamard, R. Kanaan, V. Boussaud, D. Grenet et al.,

P. Burgel, Étude des causes de décès des patients mucoviscidosiques en France, Revue des Maladies Respiratoires, vol.32, pp.8-9, 2007.

E. Kerem, J. Reisman, M. Corey, G. J. Canny, and H. Levison, Prediction of Mortality in Patients with Cystic Fibrosis, 2010.


H. Grasemann, H. G. Wiesemann, and F. Ratjen, The importance of lung function as a predictor of 2-year mortality in mucoviscidosis

, Pneumologie, vol.49, issue.8, pp.466-469, 1995.

M. Corey, L. Edwards, H. Levison, and M. Knowles, Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis, The Journal of Pediatrics, vol.131, issue.6, pp.809-814, 1997.

C. E. Milla and W. J. Warwick, Risk of Death in Cystic Fibrosis Patients With Severely Compromised Lung Function, Chest, vol.113, issue.5, pp.1230-1234, 1998.

D. B. Rosenbluth, K. Wilson, T. Ferkol, and D. P. Schuster, Lung Function Decline in Cystic Fibrosis Patients and Timing for, Lung Transplantation Referral. Chest, vol.126, issue.2, pp.412-419, 2004.

P. A. Flume, C. Strange, X. Ye, M. Ebeling, T. Hulsey et al., Pneumothorax in Cystic Fibrosis, Chest, vol.128, issue.2, pp.720-728, 2005.

N. J. Simmonds, S. J. Macneill, P. Cullinan, and M. E. Hodson, Cystic fibrosis and survival to 40 years: a casecontrol study, European Respiratory Journal, vol.36, issue.6, pp.1277-1283, 2010.

P. A. Flume, J. R. Yankaskas, M. Ebeling, T. Hulsey, and L. L. Clark, Massive Hemoptysis in Cystic Fibrosis, Chest, vol.128, issue.2, pp.729-738, 2005.

A. G. Kaditis, M. Miligkos, A. Bossi, C. Colombo, E. Hatziagorou et al., Effect of allergic bronchopulmonary aspergillosis on FEV 1 in children and adolescents with cystic fibrosis: a European Cystic Fibrosis Society Patient Registry analysis. Archives of Disease in Childhood, vol.102, pp.742-747, 2017.

R. Scarsini, M. A. Prioli, E. G. Milano, C. Castellani, G. Pesarini et al.,

, Hemodynamic predictors of long term survival in end stage cystic fibrosis, International Journal of Cardiology, vol.202, pp.221-225, 2016.

D. Li, B. Wang, H. Wang, and Q. Liu, Prognostic significance of pulmonary hypertension in patients with cystic fibrosis: A systematic review and meta-analysis, Medicine, vol.97, issue.7, p.9708, 2018.

K. De-boer, K. L. Vandemheen, E. Tullis, S. Doucette, D. Fergusson et al., Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis, Thorax, vol.66, issue.8, pp.680-685, 2011.

T. G. Liou, F. R. Adler, S. C. Fitzsimmons, B. C. Cahill, J. R. Hibbs et al., Predictive 5-Year Survivorship Model of Cystic Fibrosis, American Journal of Epidemiology, vol.153, issue.4, pp.345-352, 2001.

T. Ferkol, M. Rosenfeld, and C. E. Milla, Cystic fibrosis pulmonary exacerbations, The Journal of Pediatrics, vol.148, issue.2, pp.259-264, 2006.

M. Rosenfeld, R. Davis, S. Fitzsimmons, M. Pepe, and B. Ramsey, Gender gap in cystic fibrosis mortality

, American Journal of Epidemiology, vol.145, issue.9, pp.794-803, 1997.

K. Mcintyre, Gender and survival in cystic fibrosis: Current Opinion in Pulmonary Medicine, vol.19, pp.692-697, 2013.

E. F. Mckone, C. H. Goss, and M. L. Aitken, CFTR Genotype as a Predictor of Prognosis in Cystic Fibrosis, Chest, vol.130, issue.5, pp.1441-1447, 2006.

G. T. O'connor, H. B. Quinton, T. Kneeland, R. Kahn, T. Lever et al.,

, Median Household Income and Mortality Rate in Cystic Fibrosis, PEDIATRICS, vol.111, issue.4, pp.333-339, 2003.

M. S. Schechter, B. J. Shelton, P. A. Margolis, and S. C. Fitzsimmons, The Association of Socioeconomic Status with Outcomes in Cystic Fibrosis Patients in the United States, American Journal of Respiratory and Critical Care Medicine, vol.163, issue.6, pp.1331-1337, 2001.

M. J. Coffey, V. Whitaker, N. Gentin, R. Junek, C. Shalhoub et al.,

K. J. Gaskin, Differences in Outcomes between Early and Late Diagnosis of Cystic Fibrosis in the Newborn Screening Era, The Journal of Pediatrics, vol.181, pp.137-145, 2017.

S. N. Harun, C. Wainwright, K. Klein, and S. Hennig, A systematic review of studies examining the rate of lung function decline in patients with cystic fibrosis, Paediatric Respiratory Reviews, vol.20, pp.55-66, 2016.

A. I. Adler, B. Shine, C. Haworth, L. Leelarathna, and D. Bilton, Hyperglycemia and Death in Cystic Fibrosis-Related Diabetes, Diabetes Care, vol.34, issue.7, pp.1577-1578, 2011.

A. Moran, D. Becker, S. J. Casella, P. A. Gottlieb, M. S. Kirkman et al., Slovis B, the CFRD Consensus Conference Committee. Epidemiology, Pathophysiology, and Prognostic Implications of Cystic Fibrosis-Related Diabetes: A technical review, vol.33, pp.2677-2683, 2010.

C. Lewis, S. M. Blackman, A. Nelson, E. Oberdorfer, D. Wells et al., Diabetesrelated Mortality in Adults with Cystic Fibrosis. Role of Genotype and Sex, American Journal of Respiratory and Critical Care Medicine, vol.191, issue.2, pp.194-200, 2015.

M. Rowland, C. Gallagher, C. G. Gallagher, R. Ó. Laoide, G. Canny et al.,

D. Slattery and L. Daly, Outcome in patients with cystic fibrosis liver disease, Journal of Cystic Fibrosis, vol.14, issue.1, pp.120-126, 2015.

E. H. Yen, H. Quinton, and D. Borowitz, Better Nutritional Status in Early Childhood Is Associated with Improved Clinical Outcomes and Survival in Patients with Cystic Fibrosis, The Journal of Pediatrics, vol.162, issue.3, pp.530-535, 2013.

M. L. Peterson, D. R. Jacobs, and C. E. Milla, Longitudinal Changes in Growth Parameters Are Correlated With Changes in Pulmonary Function in Children With Cystic Fibrosis, PEDIATRICS, vol.112, issue.3, pp.588-592, 2003.

A. L. Stephenson, M. Tom, Y. Berthiaume, L. G. Singer, S. D. Aaron et al., A contemporary survival analysis of individuals with cystic fibrosis: a cohort study, European Respiratory Journal, vol.45, issue.3, pp.670-679, 2015.

A. W. Fogarty, J. Britton, A. Clayton, and A. R. Smyth, Are Measures of Body Habitus Associated With Mortality in Cystic Fibrosis?, Chest, vol.142, issue.3, pp.712-717, 2012.

J. M. Courtney, J. Bradley, J. Mccaughan, T. M. O'connor, C. Shortt et al., Predictors of mortality in adults with cystic fibrosis, Pediatric Pulmonology, vol.42, issue.6, pp.525-532, 2007.

J. Emerson, M. Rosenfeld, S. Mcnamara, B. Ramsey, and R. L. Gibson, Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis, Pediatric Pulmonology, vol.34, issue.2, pp.91-100, 2002.

M. W. Konstan, J. S. Wagener, D. R. Vandevanter, D. J. Pasta, A. Yegin et al., RISK FACTORS FOR RATE OF DECLINE IN FEV1 IN ADULTS WITH CYSTIC FIBROSIS, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, vol.11, issue.5, pp.405-411, 2012.

A. M. Jones, M. E. Dodd, J. Govan, V. Barcus, C. J. Doherty et al., Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis, Thorax, vol.59, issue.11, pp.948-951, 2004.

J. M. Courtney, K. Dunbar, A. Mcdowell, J. E. Moore, T. J. Warke et al., Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults, Journal of Cystic Fibrosis, vol.3, issue.2, pp.93-98, 2004.

R. Somayaji, C. H. Goss, U. Khan, M. Neradilek, K. M. Neuzil et al., Cystic Fibrosis Pulmonary Exacerbations Attributable to Respiratory Syncytial Virus and Influenza: A Population-Based Study, Clinical Infectious Diseases, vol.64, issue.12, pp.1760-1767, 2017.

C. L. Ren, W. J. Morgan, M. W. Konstan, M. S. Schechter, J. S. Wagener et al., Regelmann WE, for The Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Presence of methicillin resistantStaphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function, Pediatric Pulmonology, vol.42, issue.6, pp.513-518, 2007.

E. C. Dasenbrook, Association Between Respiratory Tract Methicillin-Resistant Staphylococcus aureus and Survival in Cystic Fibrosis, JAMA, vol.303, issue.23, p.2386, 2010.

R. Amin, A. Dupuis, S. D. Aaron, and F. Ratjen, The Effect of Chronic Infection With Aspergillus fumigatus on Lung Function and Hospitalization in Patients With Cystic Fibrosis, Chest, vol.137, issue.1, pp.171-176, 2010.

C. R. Esther, D. A. Esserman, P. Gilligan, A. Kerr, and P. G. Noone, Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, p.2020, 2010.


V. Waters, Y. Yau, S. Prasad, A. Lu, E. Atenafu et al., Stenotrophomonas maltophilia in Cystic Fibrosis: Serologic Response and Effect on Lung Disease, American Journal of Respiratory and Critical Care Medicine, vol.183, issue.5, pp.635-640, 2011.

V. Waters, E. G. Atenafu, A. Lu, Y. Yau, E. Tullis et al., Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients, Journal of Cystic Fibrosis, vol.12, issue.5, pp.482-486, 2013.

E. E. Barsky, K. A. Williams, G. P. Priebe, and G. S. Sawicki, Incident Stenotrophomonas maltophilia infection and lung function decline in cystic fibrosis, Pediatric Pulmonology, vol.52, issue.10, pp.1276-1282, 2017.

C. H. Goss, Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis

, Thorax, vol.59, issue.11, pp.955-959, 2004.

M. Tetart, F. Wallet, M. Kyheng, S. Leroy, T. Perez et al., Impact of Achromobacter xylosoxidans isolation on the respiratory function of adult patients with cystic fibrosis, ERJ Open Research, p.2020, 2019.


T. Bienvenu, M. Viel, C. Leroy, F. Cartault, J. F. Lesure et al., Spectrum of CFTR Mutations on Reunion Island: Effect of Neonatal Screening, Human Biology, vol.77, issue.5, pp.705-714, 2005.

H. Flodrops, M. Renouil, F. Lesure, D. Maréchal, S. Piyaraly et al., Aspects cliniques et spécificités génétiques de la mucoviscidose à l'île de la Réunion, Archives de Pédiatrie, vol.10, issue.11, pp.955-959, 2003.

F. Chevalier-porst, J. C. Chomel, D. Hillaire, A. Kitzis, J. C. Kaplan et al., A nonsense mutation in exon 4 of the cystic fibrosis gene frequent among the population of the Reunion Island, Human Molecular Genetics, vol.1, issue.8, pp.647-648, 1992.

T. Bienvenu, F. Cartault, F. Lesure, M. Renouil, C. Beldjord et al., A Splicing Mutation in Intron 16 of the Cystic Fibrosis Transmembrane Conductance Regulator Gene, Is Common on Reunion Island. Human Heredity, vol.46, issue.3, pp.168-171, 1996.

F. Cwtuult, J. Stefjrrrnn, D. Viduud, S. Botrsquet, F. Lestire et al.,

C. Bienvenu and T. , Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G, S1255L) and one novel polymorphism (L49L), Clinical Genetics, vol.54, issue.5, pp.437-439, 1998.

I. Duguépéroux, G. Bellis, J. Lesure, M. Renouil, H. Flodrops et al., Cystic fibrosis at the Reunion Island (France): spectrum of mutations and genotype-phenotype for the Y122X mutation, Journal of Cystic Fibrosis, vol.3, issue.3, pp.185-188, 2004.

D. Ho, A. Payet, C. Tasset, J. Rittie, and N. Allou, Mycobactéries atypiques dans la mucoviscidose à La Réunion, Revue des Maladies Respiratoires, vol.35, p.46, 2018.

C. Simon, N. Allou, P. Schlossmacher, T. Gendry, L. Delay et al., État des lieux de la transplantation pulmonaire à la Réunion de janvier 2005 à mai 2015. Revue de Pneumologie Clinique, vol.73, pp.75-80, 2017.

M. Claustres, C. Thèze, M. Des-georges, D. Baux, E. Girodon et al., CFTR -France, a national relational patient database for sharing genetic and phenotypic data associated with rare CFTR variants, Human Mutation, vol.38, issue.10, pp.1297-1315, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02434844

M. F. Rolland-cachera, T. J. Cole, M. Sempé, J. Tichet, C. Rossignol et al., Body Mass Index variations: centiles from birth to 87 years, European Journal of Clinical Nutrition, vol.45, issue.1, pp.13-21, 1991.

, Diagnostic de la dénutrition de l'enfant et de l'adulte. Haute Autorité de Santé, 2020.

A. Guillien, S. Th, J. Regnard, and B. Degano, Les nouvelles équations de référence du Global Lung Function Initiative (GLI) pour les explorations fonctionnelles respiratoires, Revue des Maladies Respiratoires, vol.35, issue.10, pp.1020-1027, 2018.

N. J. Ronan, J. S. Elborn, and B. J. Plant, Current and emerging comorbidities in cystic fibrosis, La Presse Médicale, vol.46, issue.6, pp.125-138, 2017.

J. Macey, E. Mas, J. Languepin, and S. De-miranda, Mucoviscidose et reflux gastro-oesophagien, Revue des Maladies Respiratoires Actualités, vol.8, issue.3, pp.205-207, 2016.

A. Moran, J. Dunitz, B. Nathan, A. Saeed, B. Holme et al., Cystic Fibrosis-Related Diabetes: Current Trends in Prevalence, Incidence, and Mortality. Diabetes Care, vol.32, pp.1626-1631, 2009.

A. Pauwels, A. Decraene, K. Blondeau, V. Mertens, R. Farre et al.,

L. J. Dupont, Bile acids in sputum and increased airway inflammation in patients with cystic fibrosis, Chest, vol.141, issue.6, pp.1568-1574, 2012.

D. Debray, Archives de Pédiatrie, vol.19, pp.23-26, 2012.

H. Guénard and S. Rouatbi,

, Revue Des Maladies Respiratoires, vol.21, issue.5, pp.8-13, 2004.

D. Taylor-robinson, M. Whitehead, F. Diderichsen, H. V. Olesen, T. Pressler et al.,

, Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study, Thorax, vol.67, issue.10, pp.860-866, 2012.

R. D. Szczesniak, D. Li, W. Su, C. Brokamp, J. Pestian et al., Phenotypes of Rapid Cystic Fibrosis Lung Disease Progression during Adolescence and Young Adulthood, American Journal of Respiratory and Critical Care Medicine, vol.196, issue.4, pp.471-478, 2017.

M. W. Konstan, J. S. Wagener, and D. R. Vandevanter, Characterizing aggressiveness and predicting future progression of CF lung disease, Journal of Cystic Fibrosis, vol.8, pp.15-19, 2009.

J. Cogen, J. Emerson, D. B. Sanders, C. Ren, M. S. Schechter et al., Risk factors for lung function decline in a large cohort of young cystic fibrosis patients: Lung Function Decline Risk Factors in Pediatric CF, Pediatric Pulmonology, vol.50, issue.8, pp.763-770, 2015.

W. J. Morgan, D. R. Vandevanter, D. J. Pasta, A. J. Foreman, J. S. Wagener et al.,

M. , L. T. Mccolley, and S. , Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with

, Cystic Fibrosis at Risk of Greater Loss of Lung Function, The Journal of Pediatrics, vol.169, pp.116-121, 2016.

E. Kerem, L. Viviani, A. Zolin, S. Macneill, E. Hatziagorou et al.,

H. Olesen, Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS Patient Registry

, European Respiratory Journal, vol.43, issue.1, pp.125-133, 2014.

T. Qvist, D. Taylor-robinson, E. Waldmann, H. V. Olesen, C. R. Hansen et al., Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis, Journal of Cystic Fibrosis, vol.15, issue.3, pp.380-385, 2016.

C. L. Harness-brumley, A. C. Elliott, D. B. Rosenbluth, D. Raghavan, and R. Jain, Gender Differences in Outcomes of Patients with Cystic Fibrosis, Journal of Women's Health, vol.23, issue.12, pp.1012-1020, 2014.

D. Salvatore, R. Buzzetti, and G. Mastella, Update of literature from cystic fibrosis registries 2012-2015. Part 6: Epidemiology, nutrition and complications: Non-Pulmonary Topics From Cystic Fibrosis Registries

, Pediatric Pulmonology, vol.52, issue.3, pp.390-398, 2017.

, Naissances et décès sont stables en 2017 -Insee Flash Réunion -148, 2020.

A. Filipovic-pierucci, A. Rigault, A. Fagot-campagna, and P. Tuppin, L'état de santé des populations des départements d'outre-mer en 2012, comparativement à la métropole : une analyse de la base nationale de l'Assurance maladie. Revue d'Épidémiologie et de Santé Publique, vol.64, pp.175-183, 2016.

. Tdb_diabete_2015 and . Pdf, , 2020.

F. Favier, I. Jaussent, N. L. Moullec, X. Debussche, M. Boyer et al., Prevalence of Type 2 diabetes and central adiposity in La Réunion Island, the REDIA Study, Diabetes Research and Clinical Practice, vol.67, issue.3, pp.234-242, 2005.

K. Ramsay, R. Stockwell, S. Bell, and T. Kidd, Infection in cystic fibrosis: impact of the environment and climate, Expert Review of Respiratory Medicine, vol.10, issue.5, pp.505-519, 2016.

H. Flodrops, M. Renouil, F. Lesure, D. Maréchal, S. Piyaraly et al., Aspects cliniques et spécificités génétiques de la mucoviscidose à l'île de la Réunion, Archives de Pédiatrie, vol.10, issue.11, pp.955-959, 2003.

É. Entre, , 2006.

, Contexte : La mucoviscidose est une maladie autosomique récessive létale dont l'incidence et la prévalence sont élevées à La Réunion

, Objectifs : Décrire la morbi-mortalité des patients réunionnais atteints de mucoviscidose

M. Matériel, Etude de cohorte observationnelle rétrospective, à partir des données du Registre Français de la Mucoviscidose sur une période de 12 ans, 2006.

, La proportion d'adultes a augmenté pendant l'étude mais représentait seulement 37% des patients en 2017, Résultats : 157 patients ont été inclus (87 hommes

, Seconde (VEMS) : durée de suivi (p<0,001), année de naissance (p<0,05), VEMS initial (p<0,001), génotype F508del/Y122X (p<0,05), colonisation chronique à Pseudomonas aeruginosa (p<0,001), bactériologie des crachats positive à mycobactérie atypique (p<0,05)

L. Diabète and . Le-reflux-gastro-oesophagien, RGO) étaient les principales complications chroniques émergentes, avec 42% d'adultes diabétiques (22/53) et une prévalence du RGO de 49% (67/138) en 2017. Seize patients (10%) sont décédés au cours de l'étude, l'atteinte cardiorespiratoire représentait 56% des décès. La mortalité a baissé de 18 à 2,4/1000 pendant l'étude

, Discussion : La mortalité a diminué au cours de la dernière décennie chez les patients réunionnais atteints de mucoviscidose. Cependant, la survie restait inférieure à la métropole, même si la différence était moins marquée chez les patients les plus jeunes